Multiple myeloma - bortezomib (TA129)
Fast, easy summary view of NICE guidance on 'blood and bone marrow cancers'
This guidance recommends bortezomib monotherapy as a possible treatment for progressive multiple myeloma for people:
- whose multiple myeloma has relapsed for the first time after having one treatment, and
- who have had a bone marrow transplant, unless it is not suitable for them.
- After not more than four cycles of treatment, a blood or urine test should be done to check how well the cancer has responded to bortezomib.
- Treatment should be continued only if there has been at least a partial response to the drug.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: blood and bone marrow cancers
- Multiple myeloma - bortezomib: review decision - November 2012
- Multiple myeloma - bortezomib: review proposal - March 2012
- TA129 Multiple myeloma - bortezomib: review update - November 2011
- TA129 Multiple myeloma - bortezomib: review update - January 2011
- NICE guidance on bortezomib (Velcade) is a win-win solution for multiple myeloma patients and the NHS
This page was last updated: 14 January 2014
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA129 Monotherapi bortezomib ar gyfer myeloma lluosog ailwael: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.